AM-411
From Wikipedia, the free encyclopedia
 |
|
|
AM-411
|
|
| Systematic (IUPAC) name | |
| (6aR,10aR)-3-(1-adamantyl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C26H34O2 |
| Mol. mass | 378.546 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
AM-411 is an analgesic drug which is a cannabinoid agonist. It is a derivative of Δ8THC substituted with an adamantyl group at the 3-position, demonstrating that the binding pocket for the alkyl chain at this position can accommodate significant bulk.
AM-411 is a potent and fairly selective CB1 full agonist with a Ki of 6.80nM, but is still also a moderately potent CB2 agonist with a Ki of 52.0nM.[1] It produces similar effects to other cannabinoid agonists such as analgesia, sedation and anxiolysis.[2][3]
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
[edit] References
- ^ Lu D, Meng Z, Thakur GA, Fan P, Steed J, Tartal CL, Hurst DP, Reggio PH, Deschamps JR, Parrish DA, George C, Järbe TU, Lamb RJ, Makriyannis A. Adamantyl cannabinoids: a novel class of cannabinergic ligands. Journal of Medicinal Chemistry. 2005 Jul 14;48(14):4576-85. PMID 15999995
- ^ Järbe TU, DiPatrizio NV, Lu D, Makriyannis A. (-)-Adamantyl-delta8-tetrahydrocannabinol (AM-411), a selective cannabinoid CB1 receptor agonist: effects on open-field behaviors and antagonism by SR-141716 in rats. Behavioural Pharmacology. 2004 Nov;15(7):517-21. PMID 15472574
- ^ McLaughlin PJ, Lu D, Winston KM, Thakur G, Swezey LA, Makriyannis A, Salamone JD. Behavioral effects of the novel cannabinoid full agonist AM 411. Pharmacology, Biochemistry and Behaviour. 2005 May;81(1):78-88. PMID 15894067
|
|||||||||||||||||||||||||||||||||||||
